Goldfinch Bio to Present at BioCentury’s Future Leaders in Biotech Industry Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Goldfinch Bio, a company singularly focused on discovering and developing precision therapies to treat patients with kidney disease, today announced that Anthony Johnson, M.D., president and chief executive officer, will present a corporate overview at BioCentury’s 25th Annual Future Leaders in the Biotech Industry Conference on Friday, March 23, 2018 at 11:30 am Eastern Time. The conference is being held at the Millennium Broadway Hotel in New York City.

About Goldfinch Bio
Goldfinch Bio is a biotechnology company committed to discover and develop precision medicines for patients with kidney disease. Just as the goldfinch has long been a symbol of healing and renewal and was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for people with kidney disease. Goldfinch was launched in 2016 by Third Rock Ventures, and is headquartered in Cambridge, Mass. For more information, please visit www.goldfinchbio.com.